{"Ticker": "IDXX", "Company": "Idexx Laboratories", "Sector": "Health Care", "Updated": "2022-05-05", "Rating": [{"Date": "2022-05-05", "Rating": "Downgrade", "Organization": "BofA Securities", "Rating_Change": "Buy to Neutral", "Target_Change": "$550 to $470"}, {"Date": "2022-02-08", "Rating": "Initiated", "Organization": "Atlantic Equities", "Rating_Change": "Overweight", "Target_Change": "$650"}, {"Date": "2021-11-18", "Rating": "Initiated", "Organization": "Morgan Stanley", "Rating_Change": "Overweight", "Target_Change": ""}, {"Date": "2021-08-05", "Rating": "Resumed", "Organization": "Credit Suisse", "Rating_Change": "Outperform", "Target_Change": "$735"}, {"Date": "2021-07-12", "Rating": "Downgrade", "Organization": "Guggenheim", "Rating_Change": "Buy to Neutral", "Target_Change": ""}, {"Date": "2021-02-17", "Rating": "Initiated", "Organization": "Barclays", "Rating_Change": "Overweight", "Target_Change": "$600"}, {"Date": "2019-09-09", "Rating": "Initiated", "Organization": "Goldman", "Rating_Change": "Neutral", "Target_Change": "$277"}, {"Date": "2019-05-23", "Rating": "Initiated", "Organization": "Guggenheim", "Rating_Change": "Buy", "Target_Change": "$276"}, {"Date": "2018-11-02", "Rating": "Reiterated", "Organization": "BofA/Merrill", "Rating_Change": "Buy", "Target_Change": "$275 to $235"}, {"Date": "2018-05-07", "Rating": "Reiterated", "Organization": "Stifel", "Rating_Change": "Buy", "Target_Change": "$215 to $225"}, {"Date": "2018-01-16", "Rating": "Initiated", "Organization": "Piper Jaffray", "Rating_Change": "Overweight", "Target_Change": "$200"}, {"Date": "2017-08-23", "Rating": "Upgrade", "Organization": "BofA/Merrill", "Rating_Change": "Neutral to Buy", "Target_Change": ""}, {"Date": "2017-07-28", "Rating": "Upgrade", "Organization": "CL King", "Rating_Change": "Neutral to Buy", "Target_Change": ""}, {"Date": "2017-02-03", "Rating": "Downgrade", "Organization": "Feltl & Co.", "Rating_Change": "Hold to Sell", "Target_Change": ""}, {"Date": "2016-09-29", "Rating": "Resumed", "Organization": "BofA/Merrill", "Rating_Change": "Neutral", "Target_Change": ""}, {"Date": "2016-08-16", "Rating": "Reiterated", "Organization": "Stifel", "Rating_Change": "Buy", "Target_Change": "$120 to $125"}, {"Date": "2016-08-03", "Rating": "Upgrade", "Organization": "Northcoast", "Rating_Change": "Sell to Neutral", "Target_Change": ""}, {"Date": "2016-07-20", "Rating": "Reiterated", "Organization": "Canaccord Genuity", "Rating_Change": "Buy", "Target_Change": "$90 to $98"}, {"Date": "2016-04-19", "Rating": "Reiterated", "Organization": "Canaccord Genuity", "Rating_Change": "Buy", "Target_Change": "$80 to $85"}, {"Date": "2016-04-01", "Rating": "Initiated", "Organization": "CL King", "Rating_Change": "Neutral", "Target_Change": ""}, {"Date": "2016-03-21", "Rating": "Reiterated", "Organization": "Stifel", "Rating_Change": "Buy", "Target_Change": "$80 to $85"}, {"Date": "2016-02-04", "Rating": "Initiated", "Organization": "Credit Suisse", "Rating_Change": "Outperform", "Target_Change": ""}]}